danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics 
Welcome,         Profile    Billing    Logout  
 20 Diseases   7 Trials   7 Trials   216 News 


1234»
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Trial completion date, Trial primary completion date:  PEMDA-HN: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (clinicaltrials.gov) -  Apr 9, 2024   
    P2,  N=81, Recruiting, 
    The SCORES study in recurrent and/or metastatic (RM) HNSCC patients, na Trial completion date: Aug 2025 --> May 2026 | Trial primary completion date: Sep 2024 --> May 2025
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Trial completion date, Trial initiation date, Trial primary completion date, Monotherapy:  Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML (clinicaltrials.gov) -  Nov 30, 2023   
    P1,  N=24, Not yet recruiting, 
    Phase classification: P1b --> P1 | Trial completion date: Sep 2023 --> Jun 2024 Trial completion date: Dec 2027 --> Mar 2028 | Initiation date: Oct 2023 --> Jan 2024 | Trial primary completion date: Mar 2025 --> Jun 2025
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Trial initiation date:  PEMDA-HN: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (clinicaltrials.gov) -  Nov 30, 2023   
    P2,  N=81, Recruiting, 
    Trial completion date: Dec 2027 --> Mar 2028 | Initiation date: Oct 2023 --> Jan 2024 | Trial primary completion date: Mar 2025 --> Jun 2025 Initiation date: Dec 2023 --> May 2023
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    P2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Immuno-oncology:  Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase 2 NeoCOAST Platform Trial. (Pubmed Central) -  Nov 3, 2023   
    Safety profiles for the combinations were similar to that of durvalumab alone. Multiplatform immune profiling suggested improved MPR rates in the durvalumab plus oleclumab and durvalumab plus monalizumab arms were associated with enhanced effector immune infiltration of tumors, interferon responses and markers of tertiary lymphoid structure formation, and systemic functional immune-cell activation.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Enrollment open, Monotherapy:  Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML (clinicaltrials.gov) -  Oct 4, 2023   
    P1,  N=24, Recruiting, 
    Multiplatform immune profiling suggested improved MPR rates in the durvalumab plus oleclumab and durvalumab plus monalizumab arms were associated with enhanced effector immune infiltration of tumors, interferon responses and markers of tertiary lymphoid structure formation, and systemic functional immune-cell activation. Not yet recruiting --> Recruiting
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Trial initiation date:  PEMDA-HN: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (clinicaltrials.gov) -  Aug 21, 2023   
    P2,  N=81, Recruiting, 
    Results support evaluation of circulating tumor DNA as a biomarker for clinical response. Initiation date: Jun 2023 --> Sep 2023
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Enrollment change, Trial completion date, Trial primary completion date, Metastases:  MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) -  Jun 1, 2023   
    P1,  N=175, Active, not recruiting, 
    The SCORES Study (ESMO 2018) in RM HNSCC patients na N=258 --> 175 | Trial completion date: Mar 2026 --> May 2023 | Trial primary completion date: Mar 2026 --> May 2023
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
    Enrollment open:  PEMDA-HN: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (clinicaltrials.gov) -  May 24, 2023   
    P2,  N=81, Recruiting, 
    N=258 --> 175 | Trial completion date: Mar 2026 --> May 2023 | Trial primary completion date: Mar 2026 --> May 2023 Not yet recruiting --> Recruiting
  • ||||||||||  HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy (Hall C7) -  Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_817;    
    P2
    Here we present mature efficacy and safety results for the initial combinations - durvalumab plus: olaparib (PARP inhibitor; Module 1), danvatirsen (STAT3 inhibitor; Module 2), ceralasertib (ATR inhibitor; Module 3), and oleclumab (anti-CD73 antibody; Module 5). Durvalumab plus ceralasertib demonstrated a promising efficacy signal, with a tolerable safety profile, in patients with advanced/metastatic NSCLC following failure of anti-PD-1/PD-L1-containing immunotherapy and ≥1 platinum-doublet regimen.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Trial completion date, Trial primary completion date, Metastases:  MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) -  May 5, 2022   
    P1,  N=212, Active, not recruiting, 
    Trial completion date: Feb 2022 --> Sep 2022 Trial completion date: Jan 2024 --> Mar 2026 | Trial primary completion date: Jan 2024 --> Mar 2026
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, danvatirsen (AZD9150) / AstraZeneca
    A Transgenic Murine Model Expressing Hyperactive STAT3 Recapitulates the Features of MDS/AML (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_4984;    
    FDA approved therapies such as the recently approved Bcl-2 inhibitor venetoclax, FLT3 inhibitors, among others, have moved the field forward in newly diagnosed MDS/AML...We have successfully demonstrated that a selective antisense oligonucleotide inhibitor of STAT3, Danvatirsen, is rapidly incorporated into MDS/AML HSPCs and induces selective apoptosis and downregulation of STAT3 in these cells in comparison with healthy control HSPCs...Through the generation of a STAT3C-vavCre mouse model, that recapitulates the features of MDS/AML, we aim to further our understanding of the molecular mechanisms and pathways that play an important role in MDS to AML transformation and will help us identify downstream mediators of this event that can be therapeutically targeted. We would also like to use this murine model as an ideal substrate for preclinical studies of STAT3 targeting therapies in hematologic malignancies such as previously reported antisense inhibitors of STAT3 and STAT3 degraders.
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Journal:  Should We Strive to Make Science Bias-Free? A Philosophical Assessment of the Reproducibility Crisis. (Pubmed Central) -  Nov 2, 2021   
    This conclusion sets the stage for an assessment of the view that evidential relations in science are inherently value-laden, a view championed by Heather Douglas and Kevin Elliott. I argue, in response to Douglas and Elliott, and as motivated by the meta-scientific resistance scientists harbour to a publication bias, that if we advocate the value-ladenness of science the result would be a deepening of the reproducibility crisis.
  • ||||||||||  danvatirsen (AZD9150) / AstraZeneca
    Journal:  Research on bilingualism as discovery science. (Pubmed Central) -  Oct 29, 2021   
    We propose and illustrate by drawing from previous and contemporary examples within brain and cognitive sciences, that this necessitates exploring the neural bases of bilingual phenotypes:the adaptive variety induced through the interplay of biology and culture. We identify the conceptual and methodological prerequisites for such exploration and briefly allude to the publication practices that afford it as a community practice and to the risk of allowing methodological prescriptions, rather than discovery, to dominate the research endeavor.